Beverly, MA – According to filings with the U.S. Securities and Exchange Commission, Akston Biosciences is raising $11,793,283.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Todd Zion played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Akston Biosciences

Located in Beverly, Massachusetts, Akston Biosciences leverages its core expertise of designing novel fusion proteins to develop and manufacture new classes of biologic therapeutics for Type 1 diabetes (T1D) prevention, ultra-long acting insulin therapy, and vaccines. Founded by the team that developed the world’s first clinical glucose-responsive insulin at SmartCells, Inc. (sold to Merck & Co. in 2010), Akston has raised over $18 million in equity financing from the management team and private investors, as well as $10 million from National Institutes of Health grants and The Helmsley Charitable Trust. Akston is partnered with Dechra Pharmaceuticals PLC (DPH) to commercialize AKS-321d, a once-a-week canine insulin therapy. Akston has built a diverse pipeline of therapeutic candidates for use in both human and animal health. The human candidates cover a range of disease indications, while the animal candidates are already in clinical testing.

To learn more about Akston Biosciences, visit http://www.akstonbio.com/

Contact:
Todd Zion, President and Chief Executive Officer
978-969-3381
todd.zion@akstonbio.com
https://www.linkedin.com/in/todd-zion-6b85ab1/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved